Elevation Oncology, Inc.
NASDAQ: ELEV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph J. Ferra Jr.
- Employees
- 34
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $21.6M
- Website
- https://elevationoncology.com
Loading ELEV…
Loading profile data…Frequently asked questions about ELEV
What does Elevation Oncology, Inc. (ELEV) do?
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study foc...
Where does ELEV trade?
Elevation Oncology, Inc. (ELEV) trades on the NASDAQ Global Select.
What sector is ELEV in?
Elevation Oncology, Inc. (ELEV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Elevation Oncology, Inc.?
Joseph J. Ferra Jr. is the chief executive officer of Elevation Oncology, Inc. (ELEV).
Where is Elevation Oncology, Inc. headquartered?
Elevation Oncology, Inc. is headquartered in United States.
Does ELEV pay a dividend?
Elevation Oncology, Inc. (ELEV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ELEV go public?
Elevation Oncology, Inc. (ELEV) completed its initial public offering in 2021.